Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CDK7 | P50613 | 3/20 | 0.40 |
| ▸ | CCNH | P51946 | 3/20 | 0.40 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1597771 | 1.00 | HCRTR1 (0.47) | HCRTR1HCRTR2FDPSCCNKCCNA2 | |
| SCHEMBL1598095 | 0.82 | NPC1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1598093 | 0.82 | NPC1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1598371 | 0.81 | HCRTR2 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL1598372 | 0.81 | HCRTR2 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL1598978 | 0.80 | DPP4 (0.51) | HCRTR1HCRTR2VNN1CYP2D6DPP4 | |
| SCHEMBL1598980 | 0.80 | DPP4 (0.51) | HCRTR1HCRTR2VNN1CYP2D6DPP4 | |
| SCHEMBL6922209 | 0.79 | CYP2D6 (0.43) | HCRTR1HCRTR2VNN1CYP2D6DPP4 | |
| SCHEMBL1598429 | 0.79 | CYP2D6 (0.43) | HCRTR1HCRTR2VNN1CYP2D6DPP4 | |
| SCHEMBL2790136 | 0.77 | CNR1 (0.43) | HCRTR1HCRTR2CDK2VNN1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | HCRTR1 417/4885HCRTR2 344/4885FDPS 1864/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | HCRTR1 417/4885HCRTR2 344/4885FDPS 1864/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | HCRTR1 417/4885HCRTR2 344/4885FDPS 1864/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885FDPS 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.